NANOBIOTIX announced that partner LianBio has entered into an agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, whereby LianBio has assigned to Janssen LianBio’s exclusive rights to develop and commercialize potential first-in-class radioenhancer NBTXR3 in China, South Korea, Singapore, and Thailand.
